The Top 250 Developers of In-Vitro Diagnostics Tests for Cancer, Cardiovascular & Infectious Disease

Publisher Name :
Date: 14-Mar-2017
No. of pages: 438

Did you know?


  • Daniella Cramp is Global President, Cardiometabolic at Alere Inc..

  • Beijing Wantai Biological Pharmacy’s Beijing plant is the largest manufacturing base for the production of infectious diseases diagnostics in China.

  • MDxHealth was the winner of the 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award.

  • iTP Biomedica Corp., the Canadian developer of diagnostic tools for cancers, is oriented to collaborative co-diagnostics development.

  • Arbor Vita Corporation’s flagship product the OncoE6™ Cervical Test has proven to be the most accurate test available worldwide for detecting cervical cancer. It is the only cervical cancer test that provides real-time results at the point-of-care.

  • Response Biomedical Corp., a global leader in cardiovascular point-of-care testing,has a wide range of markers available on its RAMP® platformincluding Troponin I, CK-MB, Myoglobin, NT-proBNP and D-dimer.

  • On May 25, 2016, Philips Handheld Diagnostics announced the launch of a new handheld blood test, the Minicare I-20 system, for rapid diagnosis (< 10 minutes) of a heart attack at the point-of-care.

  • On February 1, 2017, Great Basin Scientific, Inc. announced the completion of the clinical trial and 510(k) submission to the FDA of its Bordetella Direct Test.

  • Meridian Bioscience, Inc. reported full-year fiscal 2016 net revenues of $196.1 million.

  • In July, 2016, the Swiss-based global biopharmaceutical group, Debiopharm Group™, acquired a majority holding in GenePOC, Inc., the Canadian developer of affordable, simple, and rapid point-of-care molecular diagnostic tests for infectious diseases.


These are just a tiny sample of the 1,000's of facts to be found in ‘The Top 250 Developers Of In-Vitro Diagnostics Tests For Cancer, Cardiovascular& Infectious Diseases’.

This unique and comprehensive report (438 pages) identifies and profiles the leading 250 developers of in-vitro diagnostics tests for cancer, cardiovascular and infectious diseases. They are located right across the globe from the United States and Europe to India and China.

Report Target Market:

1) In-Vitro Diagnostics Companies

Usage: competitive/financial analysis and strategic partner/alliance identification.

2) Suppliers

‘The Top 250 Developers Of In-Vitro Diagnostics Tests For Cancer, Cardiovascular & Infectious Diseases’ is perfect for suppliers of raw materials, technology and services to identify top potential customers.

3) Distributors

This report is ideal for distributors of in-vitro diagnostics instruments and tests to identify the leading manufacturers with the best products.

4) Industry Associations:

‘The Top 250 Developers Of In-Vitro Diagnostics Tests For Cancer, Cardiovascular & Infectious Diseases’ is a useful reference tool for in-vitro diagnostic associations.

Note: Most people will be aware of some of the major developers of in-vitro diagnostics tests for cancer, cardiovascular and infectious diseases such as Accugenomics, Inc., Agendia Inc., altona Diagnostics GmbH, Biocept, Inc., bioLytical Laboratories Inc.,CardioDx, Inc., GeneNews Limited, HiberGene Diagnostics and OvaGene Oncology, Inc. but this major new report looks at all 250 of the top companies companies like:


  • GenMark Diagnostics, Inc. Founded in 2010 and headquartered in Carlsbad, California, United States, GenMark Diagnostics, Inc. (NASDAQ: GNMK) is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimise patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. In June, 2016, the Company achieved the CE Mark for its ePlex® sample-to-answer multiplex molecular diagnostics System and ePlex® Respiratory Pathogen (RP) Panel and on December 22, 2016, GenMark announced that it had submitted 510(k) applications to the FDA for its ePlex® sample-to-answer System and Respiratory Pathogen (RP) Panel. The Company has revenue of $U.S. 49.2 million and 233 employees. GenMark is led by Hany Massarany, President And Chief Executive Officer.

  • Chembio Diagnostic Systems, Inc. Headquartered in Medford, New York, United States, Chembio Diagnostic Systems, Inc. (Nasdaq: CEMI) develops, manufactures, licenses and markets point-of-care diagnostic tests and technology for the detection of infectious diseases. The Company’s Dual Path Platform (DPP®) technology is providing it with a significant pipeline of business opportunities for the development and manufacture of new products. On January 10, 2017 Chembio Diagnostic Systems, Inc. announced that the Company had completed the acquisition of RVR Diagnostics Sdn Bhd (RVR), a Malaysian, privately-held manufacturer and distributor of point-of-care diagnostic tests for infectious diseases. Founded in 1985, Chembio Diagnostic Systems, Inc. had revenues of $U.S. 24.3 million in 2015. It currently has 166 employees and is led by John J. Sperzel, Chief Executive Officer.

  • Biocartis Group NV Headquartered in Mechelen, Belgium, Biocartis Group NV is an innovative commercial stage, molecular diagnostics company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis Group NV is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases, the fastest and largest growing segments of the $U.S. 5.0 billion MDx market. The Company employs 300 people and has revenue of $U.S. 16.7 million. Biocartis Group NV has been listed on Euronext Brussels (BCART) since April 2015 and is led by Rudi Pauwels, Chief Executive Officer.


Report data field structure is as follows:


  • Company Name

  • Address

  • Telephone

  • Fax

  • Email

  • Website

  • Year Established

  • Number of Employees

  • Key Executives

  • Company Description

  • Products

  • Clinical Specialties

  • Revenue ($U.S. million)

  • Location Status

  • Ownership

  • Stock Exchange/Ticker Symbol

  • Parent Company


Research Facts is one of the world’s leading companies in life sciences publishing. It has a large portfolio of best-selling reports spanning diagnostics, pharmaceuticals, biotechnology and medical devices. It’s customers include most of the world’s major companies in these sectors e.g. Abbott Laboratories, ACON Laboratories, Alcon, Allergan, Aurobindo Pharma, Axis-Shield, Baxter, Bayer, B. Braun, BD, Biomerieux, Biomet, Boehringer Ingelheim, CareFusion, Covance, Covidien, C.R. Bard, Edwards Lifesciences, Fresenius, GE Healthcare, Genzyme, HemoCue, Intuitive Surgical, Ipsen, Johnson & Johnson, Medtronic, Merit Medical Systems, Millipore, Mölnlycke Health Care, Novartis, Paul Hartmann, Philips Medical, Qiagen, Siemens Healthcare, Smith & Nephew, Synthes, Teleflex, Teva, Zentiva etc.. Research Facts also counts many multinational financial services, law and management consulting firms such as Bain & Company, McKinsey & Company and The Boston Consulting Group among its customers.

Research Facts currently has customers in some forty countries across the globe e.g. Austria, Australia, Belgium, Brazil, Canada, Cyprus, Czech Republic, Denmark, France, Germany, Finland, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Kuwait, Luxembourg, Mauritius, Netherlands, Pakistan, Peru, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, United Kingdom, and the United States.

Research Facts' reports help you make informed decisions about the markets and organisations that affect your business.


  • Learn more about your target markets and target companies

  • Top level research on all the major players in a market

  • See which organisations dominate your major markets

  • Get detailed information on particular organisations

The Top 250 Developers of In-Vitro Diagnostics Tests for Cancer, Cardiovascular & Infectious Disease

Table of Contents

N/A

  • Global Rapid Medical Diagnostic Kits Market Research Report 2017
    Published: 21-Nov-2017        Price: US 2900 Onwards        Pages: 124
    In this report, the global Rapid Medical Diagnostic Kits market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Rapid Medical Diagnostic Kits in these regions, from 2012 to 2022 (forecast), covering - North America - Europe......
  • Global In-Vitro Diagnostics (IVD) Market Size, Status and Forecast 2022
    Published: 17-Nov-2017        Price: US 3300 Onwards        Pages: 100
    This report studies the global In-Vitro Diagnostics (IVD) market, analyzes and researches the In-Vitro Diagnostics (IVD) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Roche - Siemens - Danaher - Abbott - BD - Alere - SYSMEX - BioMerieux - J&J - BIO-RAD - Hologic - KHB Market segment by Re......
  • Therapeutic Drug Monitoring (TDM) Market 2021: US, Europe, Japan--Supplier Shares, Competitive Strategies, Segment Forecasts, Innovative Technologies, Instrumentation Review
    Published: 15-Nov-2017        Price: US 8500 Onwards        Pages: 0
    Complete report $8,500. DataPack (test volumes, sales forecasts, supplier shares) $5,500.This new 313-page report from VPGMarketResearch.com contains 83 tables and provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.The report provides test volume and sales forecasts by country and m......
  • France Therapeutic Drug Monitoring (TDM) Market 2021: Supplier Shares, Competitive Strategies, Sales Segment Forecasts, Innovative Technologies, Instrumentation Review
    Published: 15-Nov-2017        Price: US 2450 Onwards        Pages: 0
    This new 247-page report from VPGMarketResearch.com provides a comprehensive analysis of the French therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Pr......
  • Germany Therapeutic Drug Monitoring (TDM) Market 2021: Supplier Shares, Competitive Strategies, Sales Segment Forecasts, Innovative Technologies, Instrumentation Review
    Published: 15-Nov-2017        Price: US 2450 Onwards        Pages: 0
    This new 249-page report from VPGMarketResearch.com provides a comprehensive analysis of the German therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Pr......
  • Italy Therapeutic Drug Monitoring (TDM) Market 2021: Supplier Shares, Competitive Strategies, Sales Segment Forecasts, Innovative Technologies, Instrumentation Review
    Published: 15-Nov-2017        Price: US 2450 Onwards        Pages: 0
    This new 247-page report from VPGMarketResearch.com provides a comprehensive analysis of the Italian therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/P......
  • Japan Therapeutic Drug Monitoring (TDM) Market 2021: Supplier Shares, Competitive Strategies, Sales Segment Forecasts, Innovative Technologies, Instrumentation Review
    Published: 15-Nov-2017        Price: US 2750 Onwards        Pages: 0
    This new 247-page report from VPGMarketResearch.com provides a comprehensive analysis of the Japanese therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/......
  • Spain Therapeutic Drug Monitoring (TDM) Market 2021: Supplier Shares, Competitive Strategies, Sales Segment Forecasts, Innovative Technologies, Instrumentation ReviewReview
    Published: 15-Nov-2017        Price: US 2450 Onwards        Pages: 0
    This new 249-page report from VPGMarketResearch.com provides a comprehensive analysis of the Spanish therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/P......
  • UK Therapeutic Drug Monitoring (TDM) Market 2021: Supplier Shares, Competitive Strategies, Sales Segment Forecasts, Innovative Technologies, Instrumentation Review
    Published: 15-Nov-2017        Price: US 2450 Onwards        Pages: 0
    This new 247-page report from VPGMarketResearch.com provides a comprehensive analysis of the UK therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Proca......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs